2025 Q4 -tulosraportti
64 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,87%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 255 | - | - | ||
| 217 | - | - | ||
| 783 | - | - | ||
| 1 000 | - | - | ||
| 217 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 450 575 | 4 450 575 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 450 575 | 4 450 575 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 t sittenSimply so foolish that they didn't clear the table last year and secured Nanexa. Then Moderna came in Dec. Now one awaits Nanexa to announce who secures the glp1 agreement; a big player. Imagine if Novo also stumbles here and in 2-3 years it turns out to be the clearly best technology for the purpose. It is completely hopeless that one is not more aggressive in trying to secure the best cards in hand for the coming years. Better to buy one technology too many than too few in these times... Simply so insane that one didn't strike much earlier (last year) and now the price of being involved has just risen and risen. And is rising as we speak. Exciting who Nanexa will announce a glp1 agreement with in a few weeks. Crazy if it doesn't become NN... Fumble on repeat
·4 t sittenRegarding rumors of upcoming reorganization and further layoffs, as well as today's resignation. I agree that it is sad that Novo Nordisk has to go that way, but I also see it as completely pure capitalist logic. My line of thought is as follows. 1. It is unlikely that the pharmaceutical industry will in the future find a more lucrative product than obesity treatment. It is the "disease" most people worldwide suffer from, if we disregard old age. 2. This means that Novo Nordisk can only lose altitude from the point where the market is taken over by generic products. 3. Novo can throw billions out the window for R&D, but they will never be able to invent a new Semaglutide. 4. This also means that Novo, with the few products they have, can never achieve a larger turnover than what they can get either by high prices and low volume, or lower prices and high volume, for obesity medication. 5. Therefore, there is nothing else for Novo Nordik now and in the next five years but to maximize sales of obesity medication, and they can ONLY do this by lowering prices and focusing on volume (because Lilly's products and pipeline are better in the next 3-4 years). 6. When the obesity market is business-wise pumped dry in 6-8 years, Novo will face a challenge if they want to maintain their market value. Conversely, in 6-8 years, Novo can pay out dividends and buy back shares for an amount that corresponds to perhaps half of today's market value. 7. Therefore, when Novo has to find new growth areas in 6-8 years, the market value may very well have fallen compared to today, but in return, shareholders have received dividends and each individual share has become more valuable due to buybacks. 8. Novo will be run very hard as a sales and production company in the coming years, because the obesity market must be "milked" as much as possible. 9. R&D will be pushed far into the background, but they will be looking for new product categories that will ensure growth in the 2030s. Either they have to spread across many categories, or they have to start finding a cure for cancer (I don't believe that, though). Maybe other things.
·2 t sittenR&D will ALWAYS be important for Novo Nordisk. It's in the company's DNA to hunt for new opportunities that others haven't yet spotted. I believe innovation going forward will only become bigger and more important. But - otherwise I agree with you that marketing, distribution, and sales will be the competence Novo must strengthen itself in to be able to extract the profits over the next 5 years.·2 t sittenYes - But I just think that what we are seeing now is a quite significant shift in the company's strategy from being research and being for the sake of the patients to it now being much more about earnings that count. It is probably an old, venerable culture that is being shut down because the logic of capitalism no longer leaves room for it. Of course, new products are important, I just think they have to realize that they will never get a new Semaglutide anyway, but now I'm repeating myself :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
64 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,87%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenSimply so foolish that they didn't clear the table last year and secured Nanexa. Then Moderna came in Dec. Now one awaits Nanexa to announce who secures the glp1 agreement; a big player. Imagine if Novo also stumbles here and in 2-3 years it turns out to be the clearly best technology for the purpose. It is completely hopeless that one is not more aggressive in trying to secure the best cards in hand for the coming years. Better to buy one technology too many than too few in these times... Simply so insane that one didn't strike much earlier (last year) and now the price of being involved has just risen and risen. And is rising as we speak. Exciting who Nanexa will announce a glp1 agreement with in a few weeks. Crazy if it doesn't become NN... Fumble on repeat
- ·4 t sittenRegarding rumors of upcoming reorganization and further layoffs, as well as today's resignation. I agree that it is sad that Novo Nordisk has to go that way, but I also see it as completely pure capitalist logic. My line of thought is as follows. 1. It is unlikely that the pharmaceutical industry will in the future find a more lucrative product than obesity treatment. It is the "disease" most people worldwide suffer from, if we disregard old age. 2. This means that Novo Nordisk can only lose altitude from the point where the market is taken over by generic products. 3. Novo can throw billions out the window for R&D, but they will never be able to invent a new Semaglutide. 4. This also means that Novo, with the few products they have, can never achieve a larger turnover than what they can get either by high prices and low volume, or lower prices and high volume, for obesity medication. 5. Therefore, there is nothing else for Novo Nordik now and in the next five years but to maximize sales of obesity medication, and they can ONLY do this by lowering prices and focusing on volume (because Lilly's products and pipeline are better in the next 3-4 years). 6. When the obesity market is business-wise pumped dry in 6-8 years, Novo will face a challenge if they want to maintain their market value. Conversely, in 6-8 years, Novo can pay out dividends and buy back shares for an amount that corresponds to perhaps half of today's market value. 7. Therefore, when Novo has to find new growth areas in 6-8 years, the market value may very well have fallen compared to today, but in return, shareholders have received dividends and each individual share has become more valuable due to buybacks. 8. Novo will be run very hard as a sales and production company in the coming years, because the obesity market must be "milked" as much as possible. 9. R&D will be pushed far into the background, but they will be looking for new product categories that will ensure growth in the 2030s. Either they have to spread across many categories, or they have to start finding a cure for cancer (I don't believe that, though). Maybe other things.·2 t sittenR&D will ALWAYS be important for Novo Nordisk. It's in the company's DNA to hunt for new opportunities that others haven't yet spotted. I believe innovation going forward will only become bigger and more important. But - otherwise I agree with you that marketing, distribution, and sales will be the competence Novo must strengthen itself in to be able to extract the profits over the next 5 years.·2 t sittenYes - But I just think that what we are seeing now is a quite significant shift in the company's strategy from being research and being for the sake of the patients to it now being much more about earnings that count. It is probably an old, venerable culture that is being shut down because the logic of capitalism no longer leaves room for it. Of course, new products are important, I just think they have to realize that they will never get a new Semaglutide anyway, but now I'm repeating myself :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 255 | - | - | ||
| 217 | - | - | ||
| 783 | - | - | ||
| 1 000 | - | - | ||
| 217 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 450 575 | 4 450 575 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 450 575 | 4 450 575 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
64 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,87%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenSimply so foolish that they didn't clear the table last year and secured Nanexa. Then Moderna came in Dec. Now one awaits Nanexa to announce who secures the glp1 agreement; a big player. Imagine if Novo also stumbles here and in 2-3 years it turns out to be the clearly best technology for the purpose. It is completely hopeless that one is not more aggressive in trying to secure the best cards in hand for the coming years. Better to buy one technology too many than too few in these times... Simply so insane that one didn't strike much earlier (last year) and now the price of being involved has just risen and risen. And is rising as we speak. Exciting who Nanexa will announce a glp1 agreement with in a few weeks. Crazy if it doesn't become NN... Fumble on repeat
- ·4 t sittenRegarding rumors of upcoming reorganization and further layoffs, as well as today's resignation. I agree that it is sad that Novo Nordisk has to go that way, but I also see it as completely pure capitalist logic. My line of thought is as follows. 1. It is unlikely that the pharmaceutical industry will in the future find a more lucrative product than obesity treatment. It is the "disease" most people worldwide suffer from, if we disregard old age. 2. This means that Novo Nordisk can only lose altitude from the point where the market is taken over by generic products. 3. Novo can throw billions out the window for R&D, but they will never be able to invent a new Semaglutide. 4. This also means that Novo, with the few products they have, can never achieve a larger turnover than what they can get either by high prices and low volume, or lower prices and high volume, for obesity medication. 5. Therefore, there is nothing else for Novo Nordik now and in the next five years but to maximize sales of obesity medication, and they can ONLY do this by lowering prices and focusing on volume (because Lilly's products and pipeline are better in the next 3-4 years). 6. When the obesity market is business-wise pumped dry in 6-8 years, Novo will face a challenge if they want to maintain their market value. Conversely, in 6-8 years, Novo can pay out dividends and buy back shares for an amount that corresponds to perhaps half of today's market value. 7. Therefore, when Novo has to find new growth areas in 6-8 years, the market value may very well have fallen compared to today, but in return, shareholders have received dividends and each individual share has become more valuable due to buybacks. 8. Novo will be run very hard as a sales and production company in the coming years, because the obesity market must be "milked" as much as possible. 9. R&D will be pushed far into the background, but they will be looking for new product categories that will ensure growth in the 2030s. Either they have to spread across many categories, or they have to start finding a cure for cancer (I don't believe that, though). Maybe other things.·2 t sittenR&D will ALWAYS be important for Novo Nordisk. It's in the company's DNA to hunt for new opportunities that others haven't yet spotted. I believe innovation going forward will only become bigger and more important. But - otherwise I agree with you that marketing, distribution, and sales will be the competence Novo must strengthen itself in to be able to extract the profits over the next 5 years.·2 t sittenYes - But I just think that what we are seeing now is a quite significant shift in the company's strategy from being research and being for the sake of the patients to it now being much more about earnings that count. It is probably an old, venerable culture that is being shut down because the logic of capitalism no longer leaves room for it. Of course, new products are important, I just think they have to realize that they will never get a new Semaglutide anyway, but now I'm repeating myself :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 255 | - | - | ||
| 217 | - | - | ||
| 783 | - | - | ||
| 1 000 | - | - | ||
| 217 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 450 575 | 4 450 575 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 450 575 | 4 450 575 | 0 | 0 |